

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years ID6537

Final stakeholder List

General All Wales Therapeutics and Toxicology
Centre
 Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products
Regulatory Agency National Association of Primary Care
 National Pharmacy Association NHS Confederation NHS Wales Joint Commissioning Committee Scottish Medicines Consortium Welsh Government Possible comparator companies None
 Relevant research groups Asthma, Allergy and Inflammation Research Trust British Association for Lung Research Cochrane Airways Group Cochrane Ear, Nose & Throat Disorders Group David Hide Asthma and Allergy Research Centre Genomics England MRC Clinical Trials Unit

Final stakeholder list for the evaluation of betula verrucosa (itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years ID6537



Consultees	Commentators (no right to submit or appeal)
Royal Pharmaceutical SocietyRoyal Society of Medicine	National Institute for Health Research
UK Clinical Pharmacy Association	Associated Public Health groupsPublic Health Wales
<u>Others</u>	UK Health Security Agency
Department of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).


<u>Commentators</u>

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example,

Final stakeholder list for the evaluation of betula verrucosa (itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years ID6537

Issue date: November 2025





the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.